Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis.

Article Details

Citation Copy to clipboard

Jordan CL, Noah TL, Henry MM

Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis.

Pediatr Pulmonol. 2016 Oct;51(S44):S61-S70. doi: 10.1002/ppul.23505.

PubMed ID

27662106 [ View in PubMed

]

Abstract

This review seeks to re-introduce cystic fibrosis (CF) clinicians to the pharmacology of drug-drug interactions among medications commonly used in CF and provide a framework for understanding these interactions among medications outside the scope of this discussion. We here focus on drugs impacted by the cytochrome P-450 (CYP450) enzyme system and on interactions involving antimicrobials, psychotropic medications, and cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Particular attention is needed when prescribing rifampin, azole antifungals and the CFTR modulators, ivacaftor, and lumacaftor/ivacaftor, in combination with other medications. The complexities of these interactions provide a strong rationale for case management by pharmacists and pharmacologists as a routine part of CF care. Pediatr Pulmonol. 2016;51:S61-S70. (c) 2016 Wiley Periodicals, Inc.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Lumacaftor	Cytochrome P450 3A4	Protein	Humans	No	Inducer	Details

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software
Ivacaftor Ritonavir	The metabolism of Ivacaftor can be decreased when combined with Ritonavir.
Ivacaftor Ketoconazole	The metabolism of Ivacaftor can be decreased when combined with Ketoconazole.
Ivacaftor Nefazodone	The metabolism of Ivacaftor can be decreased when combined with Nefazodone.
Ivacaftor Itraconazole	The metabolism of Ivacaftor can be decreased when combined with Itraconazole.
Ivacaftor Clarithromycin	The metabolism of Ivacaftor can be decreased when combined with Clarithromycin.